Mounjaro injection
Reading File
Searching the Web
Mounjaro tirzepatide injection 2025 2026 updates indications dosing
Finding Sources
Searching PubMed
tirzepatide AND "type 2 diabetes"
Reading File
Reading File
Reading File
I now have excellent, detailed information from multiple authoritative sources. Here is a comprehensive overview:
Mounjaro (Tirzepatide) Injection
What It Is
Mounjaro is the brand name for tirzepatide, the first dual GIP (glucose-dependent insulinotropic polypeptide) / GLP-1 (glucagon-like peptide-1) receptor agonist. It is a once-weekly subcutaneous injection developed by Eli Lilly.
Structurally, it is an analogue of the GIP hormone with a fatty acid chain (1,20-eicosanedioic acid) attached at lysine-20, plus two non-coded amino acid residues (alpha-aminoisobutyric acid) at positions 2 and 13, with an amidated C-terminus. This acylation allows albumin binding, giving it a half-life of approximately 117 hours (~5 days), enabling once-weekly dosing.
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Mechanism of Action
Tirzepatide activates both GIP and GLP-1 receptors simultaneously:
| Receptor | Effect |
|---|---|
| GLP-1 | Stimulates insulin secretion (glucose-dependent), inhibits glucagon, delays gastric emptying, suppresses appetite centrally |
| GIP | Enhances insulin release from pancreatic beta cells in a glucose-dependent manner |
| Combined (brain) | GIP acts synergistically with GLP-1 receptor activation in the CNS to produce greater weight loss than either alone |
Note: GIP receptor agonism is equivalent to native GIP, but GLP-1 receptor affinity is approximately 5 times weaker than native GLP-1 - yet outcomes are superior due to dual-pathway synergy.
- Harrison's Principles of Internal Medicine, 22nd Ed. (2025)
FDA-Approved Indications
- Type 2 Diabetes Mellitus (2022) - adjunct to diet and exercise for glycaemic control in adults
- Chronic Weight Management in adults with obesity or overweight (2023) - at 5-, 10-, and 15-mg doses
Dosing Schedule
| Step | Dose | Duration |
|---|---|---|
| Starting dose | 2.5 mg SC once weekly | 4 weeks |
| Step 1 | 5 mg SC once weekly | 4 weeks |
| Step 2 | 7.5 mg SC once weekly | 4 weeks |
| Step 3 | 10 mg SC once weekly | 4 weeks |
| Step 4 | 12.5 mg SC once weekly | 4 weeks |
| Maximum dose | 15 mg SC once weekly | Ongoing |
- Dose increases occur in 2.5 mg increments every 4 weeks as tolerated
- Administered subcutaneously in the abdomen, thigh, or upper arm
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Clinical Efficacy
Glycaemic control (SURPASS trials):
- Dose-dependent HbA1c reductions of 1.9% to 2.6%
- More effective than pure GLP-1 agonists (e.g., semaglutide) for HbA1c reduction
- Useful as adjunct to insulin or as insulin replacement in difficult-to-control patients
Weight loss (SURMOUNT trials):
- Average weight loss of 6.2 to 12.9 kg (dose-dependent)
- In SURMOUNT-1: up to ~20-22% body weight reduction at the highest doses
- Systematic reviews confirm tirzepatide outperforms semaglutide for weight loss in head-to-head comparisons (PMID: 40184508)
Additional benefits:
- Improved lipid profile (reduced triglycerides)
- Blood pressure reduction
- Reduction in hepatic steatosis (fatty liver)
- Goldman-Cecil Medicine, International Edition
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia type 2 (MEN2)
- Known hypersensitivity to tirzepatide
Side Effects
Common (dose-dependent, mostly mild and transient):
- Nausea
- Vomiting
- Diarrhea
- Constipation
Serious/rare:
- Pancreatitis - slightly higher rate vs. comparators (0.23 vs. 0.11 per 100 patient-years in trials); patients should seek immediate care for unexplained persistent severe abdominal pain
- Thyroid C-cell tumours (seen in rodents; relevance in humans unclear but contraindication applies)
- Renal impairment (volume depletion from GI side effects can contribute)
Drug Interactions / Practical Considerations
- When used with sulfonylureas or insulin, risk of hypoglycaemia increases - dose reduction of those agents is often required
- GI side effects are most prominent during dose titration; slow titration helps tolerability
- Monitor baseline and periodic: HbA1c, lipids, LFTs, eGFR, body weight
Comparison: Tirzepatide vs. Semaglutide
| Feature | Tirzepatide (Mounjaro) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| HbA1c reduction | 1.9 - 2.6% | ~1.0 - 1.8% |
| Weight loss | 6.2 - 12.9 kg (up to ~22%) | ~10-15% |
| Dosing | Once weekly SC | Once weekly SC |
| Max dose | 15 mg | 2.4 mg (Wegovy) |
A 2025 meta-analysis (PMID: 40184508) of direct comparative studies confirms tirzepatide produces greater weight loss than semaglutide in patients with type 2 diabetes.
Emerging / Investigational Areas
Tirzepatide is under active investigation for:
- Obstructive sleep apnea (SURMOUNT-OSA)
- Heart failure (SUMMIT trial)
- MASLD/NASH (metabolic-associated steatotic liver disease)
- Cardiovascular outcomes (SURPASS-CVOT)
A 2025 network meta-analysis in Nature Medicine (PMID: 41039116) confirms tirzepatide among the most effective pharmacological obesity treatments available.
Disclaimer: This is educational information. Mounjaro is a prescription medication. All dosing, titration, and clinical decisions should be made by a qualified healthcare provider based on individual patient assessment.
Price of this injection
Searching the Web
Mounjaro tirzepatide price cost 2025 2026 USA UK India per month
Here is a current price breakdown across major markets:
Mounjaro (Tirzepatide) - Price Guide (2026)
🇮🇳 India (as of June 2026)
Mounjaro was launched in India in March 2025 and is widely available on prescription.
| Dose | Weekly Cost | Monthly Cost |
|---|---|---|
| 2.5 mg (starter) | ₹3,281 | ₹13,125 |
| 5 mg | ~₹4,100 | ₹16,406 |
| 7.5 mg | ~₹5,156 | ₹20,625 |
| 10 mg | ~₹5,156 | ₹20,625 |
| 12.5 mg | ~₹6,445 | ₹25,781 |
| 15 mg (max) | ~₹6,445 | ₹25,781 |
- Available as both vials and KwikPens (KwikPen launched August 2025)
- These are official Eli Lilly MRP prices
- No price cut is expected in the near term - Mounjaro became India's top-selling drug at ₹100 crore/month in sales as of Oct 2025
- Source: DermaVue India pricing / Dr. Rajat Goel
🇺🇸 USA (list price, no insurance)
| Product | Monthly Cost |
|---|---|
| Mounjaro (diabetes label) | $1,023+ per month |
| Zepbound (obesity label, same drug) | $1,059+ per month |
| Compounded tirzepatide (telehealth) | $199 - $399 per month |
- With commercial insurance and a Lilly savings card, eligible patients can pay as low as $25/month
- Medicare/Medicaid coverage is limited
- Compounded versions became available when branded supply was short, but the FDA declared the shortage over in 2024; availability of compounded versions is now legally contested
🇬🇧 UK (private prescription)
| Dose | Monthly Cost (post-Sept 2025) |
|---|---|
| 2.5 mg | ~£133/month |
| 12.5 mg - 15 mg | £330/month (~₹37,000) |
- NHS patients who qualify under NICE guidance pay nothing (NHS-commissioned tirzepatide is unaffected by private price hikes)
- Private list prices increased sharply in September 2025 (up from £92-£122 range)
- Some pharmacies offer rebate agreements with Lilly to reduce out-of-pocket cost
Quick Comparison
| Country | Monthly Cost (approx) |
|---|---|
| 🇮🇳 India | ₹13,125 - ₹25,781 (~$155 - $305) |
| 🇺🇸 USA (no insurance) | $1,023 - $1,059 (~₹86,000+) |
| 🇬🇧 UK (private) | £133 - £330 (~₹14,000 - ₹37,000) |
India is significantly more affordable than the US or UK for self-pay patients, making it one of the most accessible markets for Mounjaro globally.
Note: Prices can vary by pharmacy, city, and whether you buy vials vs. KwikPens. Always check current MRP at a registered pharmacy. Mounjaro requires a valid prescription in all countries.
This is a shared conversation. Sign in to Orris to start your own chat.